美迪西(688202.SH)回覆:未直接參與Remdesivir(瑞德西韋)抗肺炎藥物的研發
格隆匯2月4日丨美迪西(688202.SH)公佈,公司在上證E互動和股吧關注到有投資詢問公司與吉利德科學公司的合作情況,以及是否參與Remdesivir(瑞德西韋)抗肺炎藥物的研發,特回覆如下:
公司與吉利德科學公司(Gilead Sciences, Inc.)2009年開始進行合作,吉利德科學公司是公司的客户之一。公司對吉利德科學公司2019年度的銷售收入為322.89萬元,該數據尚未經會計師事務所進行審計。
公司是一家專業的生物醫藥臨牀前綜合研發服務CRO,為吉利德科學公司提供部分化合物的藥物發現,並未直接參與吉利德科學公司Remdesivir(瑞德西韋)等抗肺炎藥物的研發,吉利德科學公司對Remdesivir(瑞德西韋)抗肺炎藥物的研發結果不會對公司的業務和收入產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.